Idexx Laboratories has agreed a deal with the diagnostics company Applied BioCode to deliver new multiplex technology for its veterinary laboratory customers.
The exclusive global agreement will bring Applied BioCode's digital multiplex platform to IDEXX Reference Laboratories customers, with the technology expected to be rolled out commercially starting in 2019.
“Idexx Laboratories has agreed to bring Applied BioCode's digital multiplex platform to Idexx Reference Laboratories customers next year.“
When paired with Idexx's proprietary assays and reagents, Applied BioCode's technology will facilitate the development of ultra-high sensitivity immunoassay platforms, meaning users of products such as Idexx Snap tests will be able to carry out vector-borne disease and parasitology research, as well as treating and preventing disease.
This supports Idexx's broader goal of ensuring its customers have access to the most comprehensive, cost-effective and timely diagnostic solutions available.
Jonathan Ayers, chairman and chief executive officer of Idexx Laboratories, said: "Implementation of Applied BioCode's technology supports our vision for margin expansion, and it will allow us to offer customers expanded test menu breadth and menu customisation for each patient sample submitted to Idexx Reference Laboratories in the future."
With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Animal Health